(Source: Truveta, May 2026) Important limitation from the researchers themselves: This analysis covered only semaglutide and tirzepatide, and did not account for other common PCOS treatments such as metformin, combined oral contraceptives, or anti-androgen therapies
These lipid modifications, combined with weight loss and improved glycemic control, contribute to a more favorable cardiometabolic profile and may reduce the risk of cardiovascular events
Also noteworthy: It was an observational study, which did not prove cause-and-effect
With such high stakes at play, and with more companies hoping to capitalise on the success of recent obesity drugs, a key strategy for market leaders such as Novo Nordisk and Eli Lilly to retain dominance and competitive advantage will, in part, rely on having a strong IP and patent portfolio surrounding these therapies
This has been especially true with the growth of such practices in the spa industry, where many establishments offer glutathione infusions as a "skin lightening" treatment, for energy, or to improve sports performance